The epidermal growth factor receptor and its inhibition in cancer therapy.
暂无分享,去创建一个
[1] G. Powis. Signalling pathways as target for anticancer drug development , 1994 .
[2] A. Levitzki. Targeting signal transduction for disease therapy , 1997, Medical oncology.
[3] D. Tindall,et al. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line , 1998, The Prostate.
[4] Y. Nio,et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. , 1997, Anticancer research.
[5] N. Haites,et al. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. , 1996, European journal of cancer.
[6] K. Gibson,et al. Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines , 1997 .
[7] Y. Kuratomi,et al. Thioridazine enhances lysosomal accumulation of epidermal growth factor and toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin. , 1986, Experimental cell research.
[8] D. Davies,et al. Targeting the epidermal growth factor receptor for therapy of carcinomas. , 1996, Biochemical pharmacology.
[9] A. Klippel,et al. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.
[10] T. Tzai,et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. , 1997, Anticancer research.
[11] H. Heinzl,et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. , 1997, Anticancer research.
[12] T. Beckers,et al. Overexpression of EGFR and c‐erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts , 1998, FEBS letters.
[13] R. Kannagi,et al. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. , 1996, Oncology.
[14] A. Wells,et al. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals , 1995, Clinical & Experimental Metastasis.
[15] J. Arends,et al. CD44v6 is not a prognostic factor in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] P. Low,et al. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] N. Goldstein,et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[18] S. Takashima,et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. , 1995, Japanese journal of clinical oncology.
[19] J. Mendelsohn,et al. Epidermal growth factor receptor family and chemosensitization. , 1997, Journal of the National Cancer Institute.
[20] C. Bucana,et al. Preferential Activation of the Epidermal Growth Factor Receptor in Human Colon Carcinoma Liver Metastases in Nude Mice , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[21] P. Liberski,et al. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. , 1997, Hepato-gastroenterology.
[22] N. Shimizu,et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. , 1989, Cancer research.
[23] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[24] Alexander Levitzki,et al. Signal-transduction therapy , 1994 .
[25] E. Haber,et al. Vascular Endothelial Growth Factor Induces Heparin-binding Epidermal Growth Factor-like Growth Factor in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[26] D. Lawrence,et al. Protein kinase inhibitors: the tyrosine-specific protein kinases. , 1998, Pharmacology & therapeutics.
[27] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.
[28] M. Salgaller. American Association for Cancer Research , 2000, Expert opinion on investigational drugs.
[29] I. Pastan,et al. Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis , 1983, Cell.
[30] H. Sasano,et al. Expression of Epidermal Growth Factor‐Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors , 1997, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[31] G. Gores,et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. , 1998, Gastroenterology.
[32] A. Giordano,et al. Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer , 1998, Journal of cellular biochemistry.
[33] J G Klijn,et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.
[34] D. Shugar. Protein kinase inhibitors--potential chemotherapeutic agents. , 1995, Acta biochimica Polonica.
[35] H. Scher,et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. , 1996, Cancer research.
[36] E. Bongcam-Rudloff,et al. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. , 1997, Cancer research.
[37] American Association for Cancer Research 1997: progress and new hope in the fight against cancer. , 1997, Expert opinion on investigational drugs.
[38] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[39] D. Ruiter,et al. The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. , 1995, Biological chemistry Hoppe-Seyler.
[40] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] P. Sismondi,et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.
[42] V. Abeler,et al. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c‐erbB‐2 in early cervical squamous cell carcinoma: An immunohistochemical study , 1996, Cancer.
[43] W. Denny,et al. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. , 1998, European journal of cancer.
[44] M Hosokawa,et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[45] A. Bridges,et al. Editorial Oncologic, Endocrine & Metabolic: The current status of tyrosine kinase inhibitors: Do the diarylamine inhibitors of the EGF receptor represent a new beginning? , 1995 .
[46] D. W. Fry,et al. Inhibitors of tyrosine kinase , 1997, Current opinion in oncology.
[47] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[48] S. Rabbani,et al. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.
[49] M. Beckmann,et al. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. , 1996, Oncology.
[50] K. Gibson,et al. ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT , 1997 .
[51] L. Norton,et al. The Epidermal Growth Factor Receptor Modulates the Interaction of E-cadherin with the Actin Cytoskeleton* , 1998, The Journal of Biological Chemistry.
[52] R. Fridman,et al. Epidermal growth factor and amphiregulin up‐regulate matrix metalloproteinase‐9 (MMP‐9) in human breast cancer cells , 1997, International journal of cancer.
[53] L. Pustilnik,et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.
[54] P. Kolm,et al. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. , 1996, International journal of radiation oncology, biology, physics.
[55] P. V. van Diest,et al. Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis , 1998, The Journal of pathology.
[56] D. Neal,et al. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. , 1996, British Journal of Cancer.
[57] A. Ruíz,et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. , 1997, Clinica chimica acta; international journal of clinical chemistry.
[58] H. Modjtahedi,et al. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. , 1994, Invasion & metastasis.
[59] H. Modjtahedi,et al. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. , 1998, International journal of oncology.
[60] Kazuhiro Yoshida,et al. Expression of several growth factors and their receptor genes in human colon carcinomas , 1990, Virchows Archiv. B, Cell pathology including molecular pathology.
[61] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[62] R. Taetle,et al. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. , 1988, Journal of the National Cancer Institute.
[63] D. Davies,et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. , 1994, Biochemical pharmacology.
[64] S. Barsky,et al. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. , 1998, Anticancer research.
[65] G. Tortora,et al. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] F. Russo,et al. EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma , 1998 .
[67] Atsushi Ochiai,et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma , 1988, International journal of cancer.
[68] H. Kato,et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. , 1996, European journal of cancer.
[69] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[70] J. Grandis,et al. Downmodulation of TGF‐α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells , 1998, Journal of cellular biochemistry.
[71] A. Vecchione,et al. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. , 1997, Anticancer research.
[72] R. Khokha,et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. , 1989, Invasion & metastasis.
[73] M. Hung,et al. Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor* , 1997, The Journal of Biological Chemistry.
[74] N. Rosen,et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. , 1995, The Journal of clinical investigation.
[75] R. Derynck,et al. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.
[76] L. Norton,et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Journal of the National Cancer Institute.
[77] N. Normanno,et al. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. , 1998, Cancer detection and prevention.
[78] H. Takamura,et al. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. , 1992, Oncology.
[79] C. Bucana,et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] I. Pastan,et al. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with pseudomonas exotoxin , 1984, Journal of Cellular Physiology.
[81] P. Wersäll,et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma , 1997, Cancer Immunology, Immunotherapy.
[82] J. Lunec,et al. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. , 1998, British Journal of Cancer.
[83] D. Schuppan,et al. Prevention of EGF‐modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition , 1998, International journal of cancer.
[84] R. Lavker,et al. EGF-R dependent regulation of keratinocyte survival. , 1997, Journal of cell science.
[85] H. Bier,et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. , 1997, Anticancer research.
[86] M. Rubin,et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. , 1996, Oncogene.
[87] K. Fujikawa,et al. The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.
[88] A. Wells,et al. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis , 1994, The Journal of cell biology.
[89] C. Bucana,et al. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence , 1998 .
[90] A. Lage,et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[91] G. Kouraklis,et al. Increased estrogen receptor and epidermal growth factor receptor gene product co‐expression in surgically resected gastric adenocarcinomas , 1996, Journal of surgical oncology.
[92] S. Ranga,et al. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. , 1997, Indian journal of pathology & microbiology.
[93] G. Fontanini,et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. , 1996, Journal of the National Cancer Institute.
[94] G. Niehans,et al. Immunohistochemical staining for markers of future neoplastic progression in the larynx. , 1996, Cancer research.
[95] W. Evans,et al. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[96] Peter Traxler,et al. Protein tyrosine kinase inhibitors in cancer treatment , 1997 .
[97] R. Dickson,et al. The EGF receptor system as a target for antitumor therapy. , 1991, Cancer investigation.
[98] R. Cozens,et al. A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo , 1998 .
[99] Gary R. Grotendorst,et al. EGF and TGF‐alpha are potent chemoattractants for endothelial cells and EGF‐like peptides are present at sites of tissue regeneration , 1989, Journal of cellular physiology.
[100] F. Uckun,et al. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[101] C. Angeletti,et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[102] A. Akdaş,et al. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. , 1998, Urology.
[103] M. Volm,et al. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. , 1998, British Journal of Cancer.
[104] L. Matrisian,et al. Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.
[105] A. Vollmar,et al. Toxicity of ligand and antibody‐directed ricin A‐chain conjugates recognizing the epidermal growth factor receptor , 1987, Journal of cellular physiology.
[106] Robert S. Kerbel,et al. Establishing a Link between Oncogenes and Tumor Angiogenesis , 1998, Molecular medicine.
[107] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[108] J. Baselga,et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.
[109] R. Swerlick,et al. Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation , 1997, The EMBO journal.